doi: 10.1038/ncprheum0899.
Epub 2008 Sep 9.
Primary prevention of systemic lupus erythematosus
Affiliations
- PMID: 18779847
- DOI: 10.1038/ncprheum0899
Item in Clipboard
Primary prevention of systemic lupus erythematosus
Nat Clin Pract Rheumatol.
2008 Nov.
Abstract
In this Viewpoint, Drs Doria and Briani highlight recent advances in efforts to improve the long-term prognosis of patients with systemic lupus erythematosus. The strategies discussed aim to prevent both the occurrence of the disease and its complications.
Similar articles
-
Lupus: improving long-term prognosis.Lupus. 2008 Mar;17(3):166-70. doi: 10.1177/0961203307087612. Lupus. 2008. PMID: 18372355 Review.
-
Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?Curr Opin Rheumatol. 2009 Sep;21(5):495-500. doi: 10.1097/BOR.0b013e32832effdd. Curr Opin Rheumatol. 2009. PMID: 19593144 Review.
-
Lupoid sclerosis: what is the role of antiphospholipid antibodies?J Clin Rheumatol. 2007 Apr;13(2):85-6. doi: 10.1097/01.rhu.0000260637.95695.40. J Clin Rheumatol. 2007. PMID: 17414536
-
Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care.Lupus. 2016 Jul;25(8):838-49. doi: 10.1177/0961203316640367. Lupus. 2016. PMID: 27252260 Review.
-
How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive.Best Pract Res Clin Rheumatol. 2009 Aug;23(4):525-37. doi: 10.1016/j.berh.2009.01.009. Best Pract Res Clin Rheumatol. 2009. PMID: 19591782
Cited by
-
Protective molecules and their cognate antibodies: new players in autoimmunity.Auto Immun Highlights. 2010 Nov 4;1(2):63-72. doi: 10.1007/s13317-010-0010-8. eCollection 2010 Nov. Auto Immun Highlights. 2010. PMID: 26000109 Free PMC article. Review.
-
New therapeutic strategies in systemic lupus erythematosus management.Nat Rev Rheumatol. 2019 Jan;15(1):30-48. doi: 10.1038/s41584-018-0133-2. Nat Rev Rheumatol. 2019. PMID: 30538302 Review.
-
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.Arthritis Res Ther. 2018 May 2;20(1):85. doi: 10.1186/s13075-018-1578-z. Arthritis Res Ther. 2018. PMID: 29720240 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical